Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Here's What You Missed in Cannabis This Week » 11:29
02/02/23
02/02
11:29
02/02/23
11:29
IGC

India Globalization Capital

/

+

, TLRY

Tilray

$3.50 /

+0.16 (+4.80%)

, STMH

Stem Holdings

/

+

, INCR

InterCure

$3.81 /

+0.11 (+2.97%)

, HITI

High Tide

$1.60 /

+0.04 (+2.56%)

, FLGC

Flora Growth

/

+

, GNLN

Greenlane

/

+

, AYRWF

Ayr Wellness

$1.34 /

+0.059 (+4.61%)

, ACB

Aurora Cannabis

$1.14 /

+0.055 (+5.07%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.15 /

+0.08 (+2.61%)

, CRON

Cronos Group

$2.59 /

+0.065 (+2.58%)

, CANN

Trees Corporation

/

+

, GDNSF

Goodness Growth

/

+

, GTBIF

Green Thumb Industries

$8.45 /

+0.39 (+4.84%)

, TCNNF

Trulieve Cannabis

$6.75 /

+0.00599 (+0.09%)

, ZYNE

Zynerba

/

+

, ATAI

Atai Life Sciences

$1.90 /

+0.05 (+2.70%)

, CMPS

Compass Pathways

$10.74 /

+0.1 (+0.94%)

, RLMD

Relmada Therapeutics

$4.31 /

+0.05 (+1.17%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

TCNNF Trulieve Cannabis
$6.75 /

+0.00599 (+0.09%)

STMH Stem Holdings
/

+

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.60 /

+0.04 (+2.56%)

GTBIF Green Thumb Industries
$8.45 /

+0.39 (+4.84%)

GNLN Greenlane
/

+

GDNSF Goodness Growth
/

+

FLGC Flora Growth
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

CANN Trees Corporation
/

+

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

IGC India Globalization Capital
/

+

11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
TLRY Tilray
$3.50 /

+0.16 (+4.80%)

01/10/23 MKM Partners
Tilray price target lowered to $3 from $4 at MKM Partners
01/10/23 Canaccord
Tilray price target lowered to $5 from $7 at Canaccord
01/09/23 Alliance Global Partners
Tilray price target lowered to $3 from $4 at Alliance Global Partners
12/28/22 Piper Sandler
Tilray estimates lowered on softer beer sales at Piper Sandler
STMH Stem Holdings
/

+

INCR InterCure
$3.81 /

+0.11 (+2.97%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
HITI High Tide
$1.60 /

+0.04 (+2.56%)

FLGC Flora Growth
/

+

12/19/22 Alliance Global Partners
Flora Growth price target lowered to $1.25 from $2 at Alliance Global Partners
10/24/22 Alliance Global Partners
Flora Growth price target lowered to $2 from $2.50 at Alliance Global Partners
09/23/22 Alliance Global Partners
Flora Growth initiated with a Buy at Alliance Global Partners
08/01/22 Cantor Fitzgerald
Cantor starts Flora Growth with Neutral amid diversification process
GNLN Greenlane
/

+

11/16/22 Alliance Global Partners
Greenlane price target lowered to $2 from $6 at Alliance Global Partners
11/01/22 Roth MKM
Greenlane downgraded to Neutral from Buy at Roth Capital
08/17/22 Alliance Global Partners
Greenlane price target raised to $6 from $1.50 at Alliance Global Partners
08/17/22 Canaccord
Greenlane price target lowered to $5 from $20 at Canaccord
AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

01/30/23 Canaccord
Ayr Wellness downgraded to Speculative Buy from Buy at Canaccord
10/28/22 BTIG
Ayr Wellness initiated with a Buy at BTIG
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
08/19/22 Northland
Ayr Wellness price target lowered to $10 from $14 at Northland
ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

01/27/23 Stifel
Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel
12/28/22 Piper Sandler
Aurora Cannabis price target lowered to $1 from $2 at Piper Sandler
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
CVSI CV Sciences
/

+

CTST CannTrust
/

+

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

02/01/23 CIBC
Canopy Growth price target lowered to C$2.50 from C$3 at CIBC
11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

11/08/22 Canaccord
Cronos Group price target lowered to C$4.75 from C$5 at Canaccord
11/01/22 Bernstein
Cronos started with Market Perform on limited visibility at Bernstein
11/01/22 Bernstein
Cronos Group initiated with a Market Perform at Bernstein
CANN Trees Corporation
/

+

GDNSF Goodness Growth
/

+

11/16/22 Canaccord
Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord
10/14/22 Alliance Global Partners
Verano Holdings price target lowered to C$12 from C$16 at Alliance Global
05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
GTBIF Green Thumb Industries
$8.45 /

+0.39 (+4.84%)

12/01/22 Wedbush
Wedbush starts Green Thumb with Outperform, names top cannabis pick
12/01/22 Wedbush
Green Thumb Industries initiated with an Outperform at Wedbush
11/03/22 Stifel
Green Thumb Industries price target raised to C$31 from C$30.50 at Stifel
TCNNF Trulieve Cannabis
$6.75 /

+0.00599 (+0.09%)

12/01/22 Wedbush
Wedbush starts Trulieve with Outperform on broadening reach
12/01/22 Wedbush
Trulieve Cannabis initiated with an Outperform at Wedbush
11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
ZYNE Zynerba
/

+

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

01/19/23 H.C. Wainwright
Atai Life Sciences price target lowered to $20 from $50 at H.C. Wainwright
01/09/23 Canaccord
Atai Life Sciences price target lowered to $11 from $27 at Canaccord
01/09/23 Loop Capital
Atai Life Sciences price target lowered to $10 from $18 at Loop Capital
01/09/23 Citi
Atai Life Sciences price target lowered to $10 from $20 at Citi
CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

12/15/22 EF Hutton
Compass Pathways initiated with a Buy at EF Hutton
12/09/22 Oppenheimer
Compass Pathways price target lowered to $33 from $55 at Oppenheimer
11/01/22 Loop Capital
Compass Pathways initiated with a Buy at Loop Capital
RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

12/08/22 Truist
Relmada Therapeutics price target lowered to $4 from $7 at Truist
11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
ZYNE Zynerba
/

+

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

HITI High Tide
$1.60 /

+0.04 (+2.56%)

GNLN Greenlane
/

+

FLGC Flora Growth
/

+

CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

  • 27
    May
IGC India Globalization Capital
/

+

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.60 /

+0.04 (+2.56%)

FLGC Flora Growth
/

+

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

Over a week ago
Hot Stocks
InterCure terminates acquisition agreement with Cann Pharmaceutical » 08:33
02/01/23
02/01
08:33
02/01/23
08:33
INCR

InterCure

$3.70 /

+0.11 (+3.06%)

InterCure announces that,…

InterCure announces that, further to the merger agreement with Cann Pharmaceutical dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better, and further to the Company's press release dated November 23, 2022 regarding the fundamental disagreements between the parties, that the closing conditions contained in the Agreement were not met and the Agreement was terminated. In accordance with the terms of the Agreement, the Agreement terminates automatically if the closing conditions and the merger are not completed by 5:00 pm on 31st of January 2023. Accordingly, and in light of the fact that the closing conditions were not met by such date, the Agreement was automatically terminated. Intercure is owed significant amounts loaned and advanced to Better, and since the Agreement was terminated, it intends to recover said amounts under all legal means available to it.

ShowHide Related Items >><<
INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

Hot Stocks
SpringBig announces integration with KORONA POS » 07:12
01/25/23
01/25
07:12
01/25/23
07:12
SBIG

SpringBig

/

+

springbig introduced a…

springbig introduced a new integration with KORONA POS from software vendor COMBASE. KORONA POS and springbig's bidirectional integration will allow merchants to apply and award loyalty offerings directly from KORONA POS at checkout. Merchants will also be able to enroll new members into the loyalty program from either the POS or one of Springbig's many enrollment tools. The Company's marketing platform seamlessly integrates with KORONA POS to provide marketing segmentation based on sales data. This allows highly targeted and strategic campaigns to drive business and reach consumers in a highly personalized way.

ShowHide Related Items >><<
SBIG SpringBig
/

+

SBIG SpringBig
/

+

06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
Over a month ago
Syndicate
Chicago Atlantic files $500M mixed securities shelf  06:03
12/21/22
12/21
06:03
12/21/22
06:03
REFI

Chicago Atlantic

$15.87 /

-0.03 (-0.19%)

 
ShowHide Related Items >><<
REFI Chicago Atlantic
$15.87 /

-0.03 (-0.19%)

04/18/22 EF Hutton
Chicago Atlantic initiated with a Buy at EF Hutton
03/23/22 Oppenheimer
Chicago Atlantic price target raised to $18 from $1 at Oppenheimer
03/23/22 Oppenheimer
Chicago Atlantic price target raised to $18 from $1 at Oppenheimer
01/03/22 Lake Street
Chicago Atlantic initiated with a Buy at Lake Street
REFI Chicago Atlantic
$15.87 /

-0.03 (-0.19%)

REFI Chicago Atlantic
$15.87 /

-0.03 (-0.19%)

Hot Stocks
InterCure enters exclusive international partnership agreement with Binske » 08:41
12/19/22
12/19
08:41
12/19/22
08:41
INCR

InterCure

$4.23 /

-0.08 (-1.86%)

InterCure entered into a…

InterCure entered into a definitive licensing agreement with Praetorian Global. Pursuant to the Agreement, Praetorian Global agreed to grant InterCure an exclusive multi-year right to cultivate, manufacture, market, and distribute Binske-branded products in major global pharmaceutical markets including Israel, Germany, Australia, UK and others. The company said, "InterCure is of the view that Binske has pioneered the premium medical and recreational markets in the United States through its meticulous focus on standards, quality, and consistency. Laudedfor its proprietary strains, craft ingredients, full product suite of nearly 200 offerings, and best-in-class packaging, "Binske" offers luxury, artisan-quality products using purposefully sourced ingredients that have earned widespread recognition, making it one of the largest and most recognizable brands in the American market. The "Binske" brand has won numerous cannabis related awards including Leafly's Best Overall Brand, Best Edibles and Best Concentrates. The Company considers Binske's sophisticated product offerings, coupled with their innovative brand identity, to set them apart from the rest of the marketplace." The Agreement brings these products exclusively to Intercure's Israeli hub to manufacture and distribute all "Binske" Branded Products under EU-GMP standards, exclusively to the international pharmaceutical space. As part of the Agreement, Binske will provide the Company access to its intellectual property, including genetics, formulations and know-how for cultivation and manufacturing of Binske-branded cannabis products at the Company's facilities. In addition, "Binske" will provide InterCure with IP relating to extraction formulations and the production of downstream products developed by "Binske", and will support InterCure's team with training of manufacturing and cultivation methods that are tailored for Binske's exacting standards. Under the terms of the Agreement, InterCure will produce and distribute the Branded Products leveraging its international supply chain using the Company's medical cannabis-dedicated pharmacy chain. During the 7.5-year term of the Agreement, the same lines of core "Binske" Branded Products launched in North America will be manufactured and distributed exclusively by InterCure in the territories stipulated in the Agreement.

ShowHide Related Items >><<
INCR InterCure
$4.23 /

-0.08 (-1.86%)

INCR InterCure
$4.23 /

-0.08 (-1.86%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$4.23 /

-0.08 (-1.86%)

INCR InterCure
$4.23 /

-0.08 (-1.86%)

INCR InterCure
$4.23 /

-0.08 (-1.86%)

Hot Stocks
InterCure announces withdrawal of class action lawsuit against it » 16:39
12/05/22
12/05
16:39
12/05/22
16:39
INCR

InterCure

$4.75 /

-0.075 (-1.55%)

InterCure announced the…

InterCure announced the withdrawal of a class action lawsuit against it. The Regenera Lawsuit was described in the company's press release dated May 26, 2020 and in the company's most recent annual report and annual information form and it was primarily concerning a motion to certify, as a class action, a claim filed against the company, its directors and its executive officers, alleging that the company violated its obligation to publicly disclose certain events and developments which impacted the valuation of Regenera Pharma. On December 2, the Tel Aviv District Court approved a consent motion to withdraw the Regenera Lawsuit, without any payment to the plaintiff from the Company.

ShowHide Related Items >><<
INCR InterCure
$4.75 /

-0.075 (-1.55%)

INCR InterCure
$4.75 /

-0.075 (-1.55%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$4.75 /

-0.075 (-1.55%)

INCR InterCure
$4.75 /

-0.075 (-1.55%)

INCR InterCure
$4.75 /

-0.075 (-1.55%)

Hot Stocks
SpringBig announces cost reduction action to strengthen financial profile » 07:02
11/30/22
11/30
07:02
11/30/22
07:02
SBIG

SpringBig

/

+

SpringBig announced that…

SpringBig announced that the company is undertaking a series of initiatives to reduce costs and drive efficiency in order to accelerate its path to profitability. These cost-cutting measures will allow the company to prioritize growth opportunities, right-size its expense structure and preserve capital while strengthening its financial position. "Our focus remains on consistent execution and expanding the reach of the springbig platform, while optimizing our organization to deliver profitable growth. We believe that the steps we are announcing today will produce an annual operating expense run rate in 2023 that is expected to be approximately 21% less than annualized operating expenses incurred for the nine months ended September 30, 2022, shortening the timeline to our goal of positive EBITDA during 2023, and we continue to expect an acceleration in revenue next year," said Jeffrey Harris, CEO and Chairman of springbig. As part of the initiatives announced today, Springbig has announced a workforce reduction of 37 positions, or 23% of the company's headcount through a combination of layoffs and attrition to ensure its long-term health. The company expects a one-time cash restructuring charge for the layoffs of approximately $0.2 million in Q4 of 2022.

ShowHide Related Items >><<
SBIG SpringBig
/

+

SBIG SpringBig
/

+

06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
On The Fly
Here's What You Missed in Cannabis This Week » 11:03
11/17/22
11/17
11:03
11/17/22
11:03
RLMD

Relmada Therapeutics

$5.77 /

+ (+0.00%)

, CMPS

Compass Pathways

$10.06 /

-0.235 (-2.28%)

, ATAI

Atai Life Sciences

$2.75 /

-0.125 (-4.35%)

, ZYNE

Zynerba

/

+

, TCNNF

Trulieve Cannabis

$12.95 /

+0.45 (+3.60%)

, TLRY

Tilray

$4.00 /

-0.09 (-2.20%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$14.25 /

+ (+0.00%)

, GDNSF

Goodness Growth

/

+

, CANN

Trees Corporation

/

+

, CRON

Cronos Group

$2.92 /

-0.025 (-0.85%)

, CGC

Canopy Growth

$3.99 /

-0.085 (-2.09%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$1.40 /

-0.05 (-3.46%)

, FLGC

Flora Growth

/

+

, GRWG

GrowGeneration

$6.54 /

-0.07 (-1.06%)

, INCR

InterCure

$4.90 /

-0.21 (-4.11%)

, OGI

Organigram

$1.02 /

+0.005 (+0.50%)

, KHRNF

Khiron Life Sciences

/

+

, ETRGF

Entourage Health

/

+

, HEXO

Hexo

/

+

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$4.00 /

-0.09 (-2.20%)

TCNNF Trulieve Cannabis
$12.95 /

+0.45 (+3.60%)

RLMD Relmada Therapeutics
$5.77 /

+ (+0.00%)

OGI Organigram
$1.02 /

+0.005 (+0.50%)

INCR InterCure
$4.90 /

-0.21 (-4.11%)

IGC India Globalization Capital
/

+

HEXO Hexo
/

+

GTBIF Green Thumb Industries
$14.25 /

+ (+0.00%)

GRWG GrowGeneration
$6.54 /

-0.07 (-1.06%)

GDNSF Goodness Growth
/

+

FLGC Flora Growth
/

+

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$2.92 /

-0.025 (-0.85%)

CMPS Compass Pathways
$10.06 /

-0.235 (-2.28%)

CGC Canopy Growth
$3.99 /

-0.085 (-2.09%)

CANN Trees Corporation
/

+

ATAI Atai Life Sciences
$2.75 /

-0.125 (-4.35%)

ACB Aurora Cannabis
$1.40 /

-0.05 (-3.46%)

RLMD Relmada Therapeutics
$5.77 /

+ (+0.00%)

11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
10/14/22 Truist
Relmada Therapeutics downgraded to Hold from Buy at Truist
CMPS Compass Pathways
$10.06 /

-0.235 (-2.28%)

11/01/22 Loop Capital
Compass Pathways initiated with a Buy at Loop Capital
10/13/22 Oppenheimer
Compass Pathways price target lowered to $55 from $65 at Oppenheimer
10/13/22 Canaccord
Compass Pathways price target lowered to $50 from $78 at Canaccord
08/05/22 Cantor Fitzgerald
Compass Pathways price target lowered to $35 from $58 at Cantor Fitzgerald
ATAI Atai Life Sciences
$2.75 /

-0.125 (-4.35%)

11/01/22 Loop Capital
Atai Life Sciences initiated with a Buy at Loop Capital
09/01/22 Citi
Atai Life Sciences price target lowered to $20 from $22 at Citi
05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
ZYNE Zynerba
/

+

11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
TCNNF Trulieve Cannabis
$12.95 /

+0.45 (+3.60%)

11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
10/28/22 BTIG
Trulieve Cannabis assumed with a Buy at BTIG
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
TLRY Tilray
$4.00 /

-0.09 (-2.20%)

11/01/22 Bernstein
Tilray initiated with Market Perform, $3.90 target at Bernstein
11/01/22 Bernstein
Tilray initiated with a Market Perform at Bernstein
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$14.25 /

+ (+0.00%)

11/03/22 Stifel
Green Thumb Industries price target raised to C$31 from C$30.50 at Stifel
10/28/22 BTIG
Green Thumb Industries assumed with a Buy at BTIG
GDNSF Goodness Growth
/

+

11/16/22 Canaccord
Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord
10/14/22 Alliance Global Partners
Verano Holdings price target lowered to C$12 from C$16 at Alliance Global
05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
CANN Trees Corporation
/

+

CRON Cronos Group
$2.92 /

-0.025 (-0.85%)

11/08/22 Canaccord
Cronos Group price target lowered to C$4.75 from C$5 at Canaccord
11/01/22 Bernstein
Cronos started with Market Perform on limited visibility at Bernstein
11/01/22 Bernstein
Cronos Group initiated with a Market Perform at Bernstein
CGC Canopy Growth
$3.99 /

-0.085 (-2.09%)

11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
11/01/22 Bernstein
Canopy Growth initiated with an Underperform at Bernstein
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$1.40 /

-0.05 (-3.46%)

09/21/22 Canaccord
Aurora Cannabis upgraded to Hold from Sell at Canaccord
09/21/22 Piper Sandler
Aurora Cannabis price target lowered to $3 from $4 at Piper Sandler
FLGC Flora Growth
/

+

10/24/22 Alliance Global Partners
Flora Growth price target lowered to $2 from $2.50 at Alliance Global Partners
09/23/22 Alliance Global Partners
Flora Growth initiated with a Buy at Alliance Global Partners
08/01/22 Cantor Fitzgerald
Cantor starts Flora Growth with Neutral amid diversification process
08/01/22 Cantor Fitzgerald
Flora Growth initiated with a Neutral at Cantor Fitzgerald
GRWG GrowGeneration
$6.54 /

-0.07 (-1.06%)

11/08/22 Alliance Global Partners
GrowGeneration price target lowered to C$4 from C$4.50 at Alliance Global
08/05/22 Alliance Global Partners
GrowGeneration downgraded to Neutral from Buy at Alliance Global Partners
05/12/22 Oppenheimer
GrowGeneration price target lowered to $15 from $50 at Oppenheimer
05/11/22 Wells Fargo
GrowGeneration price target lowered to $4 from $8 at Wells Fargo
INCR InterCure
$4.90 /

-0.21 (-4.11%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
OGI Organigram
$1.02 /

+0.005 (+0.50%)

07/15/22 Stifel
Organigram price target lowered to C$1.50 from C$2.25 at Stifel
07/15/22 Alliance Global Partners
Organigram price target lowered to C$1.50 from C$2.25 at Alliance Global
01/13/22 Stifel
Organigram price target lowered to C$2.25 from C$2.75 at Stifel
01/12/22 Canaccord
Organigram upgraded to Speculative Buy from Hold at Canaccord
KHRNF Khiron Life Sciences
/

+

ETRGF Entourage Health
/

+

06/02/22 Canaccord
Entourage Health downgraded to Hold from Speculative Buy at Canaccord
11/18/21 Canaccord
Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
HEXO Hexo
/

+

06/16/22 Canaccord
Hexo downgraded to Hold at Canaccord on faltering turnaround prospects
06/15/22 Canaccord
Hexo downgraded to Hold from Speculative Buy at Canaccord
06/15/22 Alliance Global Partners
Hexo downgraded to Neutral from Buy at Alliance Global Partners
06/15/22 Canaccord
Tilray price target lowered to $7 from $9 at CanaccordHexo
ZYNE Zynerba
/

+

TLRY Tilray
$4.00 /

-0.09 (-2.20%)

RLMD Relmada Therapeutics
$5.77 /

+ (+0.00%)

INCR InterCure
$4.90 /

-0.21 (-4.11%)

HEXO Hexo
/

+

GRWG GrowGeneration
$6.54 /

-0.07 (-1.06%)

ETRGF Entourage Health
/

+

CRON Cronos Group
$2.92 /

-0.025 (-0.85%)

CMPS Compass Pathways
$10.06 /

-0.235 (-2.28%)

CGC Canopy Growth
$3.99 /

-0.085 (-2.09%)

ATAI Atai Life Sciences
$2.75 /

-0.125 (-4.35%)

ACB Aurora Cannabis
$1.40 /

-0.05 (-3.46%)

  • 27
    May
  • 09
    Dec
  • 19
    Nov
ZYNE Zynerba
/

+

RLMD Relmada Therapeutics
$5.77 /

+ (+0.00%)

INCR InterCure
$4.90 /

-0.21 (-4.11%)

HEXO Hexo
/

+

FLGC Flora Growth
/

+

ETRGF Entourage Health
/

+

ACB Aurora Cannabis
$1.40 /

-0.05 (-3.46%)

TLRY Tilray
$4.00 /

-0.09 (-2.20%)

RLMD Relmada Therapeutics
$5.77 /

+ (+0.00%)

INCR InterCure
$4.90 /

-0.21 (-4.11%)

HEXO Hexo
/

+

GRWG GrowGeneration
$6.54 /

-0.07 (-1.06%)

CGC Canopy Growth
$3.99 /

-0.085 (-2.09%)

ACB Aurora Cannabis
$1.40 /

-0.05 (-3.46%)

Hot Stocks
Organigram, InterCure enter multi-year supply agreement for dried flower » 08:20
11/17/22
11/17
08:20
11/17/22
08:20
OGI

Organigram

$1.01 /

-0.01 (-0.98%)

, INCR

InterCure

$5.13 /

-0.27 (-5.00%)

Organigram Holdings (OGI)…

Organigram Holdings (OGI) and Canndoc (INCR) jointly announced that they have entered into a new multi-year agreement for Organigram to continue supply of dried flower to InterCure. Organigram and InterCure entered into a previous strategic supply agreement in June 2020, that contemplated a minimum supply of 3,000 kg all of which has been fulfilled. The New Strategic Agreement contemplates up to 20,000 kg to be supplied to InterCure's international supply chain. Specifically, the New Strategic Agreement provides for a commitment of 10,000kg with an option for Canndoc to elect to order up to an additional 10,000kg from Organigram during the three-year term. Approximately 2,800 kg has already been delivered to Canndoc from Organigram since July 2022 and credited against the total volume commitment under the New Strategic Agreement. Based on the success of the First Strategic Agreement and the desire of the parties to continue to collaborate and grow their businesses, the New Strategic Agreement was entered into. Subject to the terms and conditions of the New Strategic Agreement, Organigram has agreed to exclusively supply InterCure in Israel for the Term. Additionally, the parties agreed on certain popular genetics which will be exclusively supplied for distribution into InterCure's international supply chain, subject to local regulations. Activities under the New Strategic Agreement are subject to compliance with all applicable laws, including receipt of all requisite approvals and permits for each proposed shipment from all applicable regulatory authorities including the Israeli Ministry of Health and Health Canada.

ShowHide Related Items >><<
OGI Organigram
$1.01 /

-0.01 (-0.98%)

INCR InterCure
$5.13 /

-0.27 (-5.00%)

OGI Organigram
$1.01 /

-0.01 (-0.98%)

07/15/22 Stifel
Organigram price target lowered to C$1.50 from C$2.25 at Stifel
07/15/22 Alliance Global Partners
Organigram price target lowered to C$1.50 from C$2.25 at Alliance Global
01/13/22 Stifel
Organigram price target lowered to C$2.25 from C$2.75 at Stifel
01/12/22 Canaccord
Organigram upgraded to Speculative Buy from Hold at Canaccord
INCR InterCure
$5.13 /

-0.27 (-5.00%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$5.13 /

-0.27 (-5.00%)

INCR InterCure
$5.13 /

-0.27 (-5.00%)

INCR InterCure
$5.13 /

-0.27 (-5.00%)

Earnings
InterCure reports Q3 EPS NIS 0.16 vs (NIS 0.03) last year » 09:12
11/15/22
11/15
09:12
11/15/22
09:12
INCR

InterCure

$5.15 /

+0.17 (+3.41%)

Reports Q3 revenue NIS…

Reports Q3 revenue NIS 100.57M vs NIS 61.695M last year "I am proud of our team delivering our eleventh consecutive quarter of profitable growth with strong operating and financial performance," said InterCure CEO Alexander Rabinovitch. "We continued to execute on our international expansion plans building our footprint organically and exploring strategic acquisitions in key markets, to meet the solid demand for our high-quality branded products. We expect 2022 to be another milestone year for InterCure, solidifying our leadership position in the pharmaceutical cannabis market."

ShowHide Related Items >><<
INCR InterCure
$5.15 /

+0.17 (+3.41%)

INCR InterCure
$5.15 /

+0.17 (+3.41%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$5.15 /

+0.17 (+3.41%)

INCR InterCure
$5.15 /

+0.17 (+3.41%)

INCR InterCure
$5.15 /

+0.17 (+3.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.